Two-year extension of a one-year, multicenter, randomized, partially-blinded study of the safety and efficacy of FTY720 [fingolimod] combined with corticosteroids and full or reduced-dose cyclosporin, USP [modified] (Novartis brand) in de novo adult renal transplant recipients.
Phase of Trial: Phase II
Latest Information Update: 24 Mar 2009
At a glance
- Drugs Fingolimod (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 14 Dec 2005 New trial record.